HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY CYP4F2 genetic variant alters required warfarin dose
نویسندگان
چکیده
1Department of Surgery, Marshfield Clinic, Marshfield, WI; 2Affymetrix, Santa Clara, CA; 3University of Florida, Gainesville; 4Washington University, St Louis, MO; 5Third Wave Technologies, Madison, WI; 6Health Services Research Center, Marshfield Clinic Research Foundation, Marshfield, WI; 7Office of Scientific Writing and Publications, Marshfield Clinic Research Foundation, Marshfield, WI; Departments of 8Cardiology, and 9General Internal Medicine, Marshfield Clinic, Marshfield, WI; 10Center for Human Genetics, Marshfield Clinic Research Foundation, Marshfield, WI; and 11Biomedical Informatics Research Center, Marshfield Clinic Research Foundation, Marshfield, WI
منابع مشابه
HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen
Current dosing algorithms do not account for genetic and environmental factors for warfarin dose determinations. This study investigated the contribution of age, CYP2C9 and VKORC1 genotype, and body size to warfarin-dose requirements. Studied were 297 patients with stable anticoagulation with a target international normalized ratio (INR) of 2.0 to 3.0. Genetic analyses for CYP2C9 (*2 and *3 all...
متن کاملHEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment
Cytochrome P-450 2C9 is the principle enzyme that terminates the anticoagulant effect of warfarin. Genetic polymorphisms in CYP2C9 producing variants with altered catalytic properties have been identified. Patients (n 5 561) with a target international normalized ratio (INR) of 2.5 who had been treated with warfarin for more than 2 months were anonymously genotyped for the wild-type CYP2C9*1 al...
متن کاملInhibition of factor XIa as a new approach to anticoagulation.
The dose-limiting issue with available anticoagulant therapies is bleeding. Is there an approach that could provide antithrombotic protection with reduced bleeding? One hypothesis is that targeting proteases upstream from the common pathway provides a reduction in thrombin sufficient to impede occlusive thrombosis yet allows enough thrombin generation to support hemostasis. The impairment of in...
متن کاملFactor VII-activating protease promotes the proteolysis and inhibition of tissue factor pathway inhibitor.
OBJECTIVE Factor VII-activating protease (FSAP) activates both factor VII and pro-urokinase and inhibits platelet-derived growth factor-BB, thus regulating hemostasis- and remodeling-associated processes in the vasculature. A genetic variant of FSAP (Marburg I polymorphism) results in low enzymatic activity and is associated with an enhanced risk of carotid stenosis and stroke. We postulate tha...
متن کاملHEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY Regression of warfarin-induced medial elastocalcinosis by high intake of vitamin K in rats
Arterial calcification (AC) is generally regarded as an independent risk factor for cardiovascular morbidity and mortality. Matrix Gla protein (MGP) is a potent inhibitor of AC, and its activity depends on vitamin K (VK). In rats, inactivation of MGP by treatment with the vitamin K antagonist warfarin leads to rapid calcification of the arteries. Here, we investigated whether preformed AC can b...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2008